Please note, Alexar has changed its name to Ralexar
Mr. Tullman brings more than 25 years of biopharmaceutical global commercialization and drug development experience. Mr. Tullman also serves as the co-founder and Managing Partner for NeXeption, LLC, and co-founder and Chairman of Aclaris Therapeutics. He was Chairman and Chief Executive Officer of Ceptaris Therapeutics (acquired by Actelion 2013), co-founder Chairman of Vicept Therapeutics (acquired by Allergan 2011), co-founder President and CEO of Ception Therapeutics, (acquired by Cephalon 2010), co-founder Trigenesis Therapeutics, a dermatology company (acquired by Reddy’s Laboratories 2004). He also served on the Board of Directors for Euromed, a wound care company. Mr. Tullman started his career at SmithKline Beecham and held positions of increasing responsibility in finance, sales, marketing, and research and development. Mr. Tullman earned a B.S. from Rutgers University in New Jersey.